Immutep Limited

23/07/2026

Immutep Limited is pleased to announce it has had an abstract accepted for presentation at the ESMO - European Society for Medical Oncology Congress 2026, taking place 23–27 October in Madrid, Spain.

The ePoster presents health-related quality of life data from the investigator-initiated EFTISARC-NEO Phase II trial, evaluating our first-in-class MHC Class II agonist, efti, in combination with pembrolizumab and radiotherapy as a neoadjuvant treatment for patients with soft tissue sarcoma.

The full abstract will be published on the ESMO Congress 2026 website on Monday, 19 October 2026, with the presentation to follow on Immutep's website.

Read more: https://bit.ly/4pK7WGg

16/07/2026

Immutep Limited CEO and Executive Director, Marc Voigt recently joined Table for Two to discuss encouraging overall survival data from the Phase I INSIGHT-003 trial, progress across the company’s clinical pipeline, and key milestones ahead.

The interview also highlights the strengthening of Immutep’s intellectual property portfolio with a fourth US patent for eftilagimod alfa (efti) and provides an update on the TACTI-004 root cause analysis.

Watch the full interview here:

Immutep Limited (ASX: IMM, NASDAQ: IMMP) - CEO and Executive Direct...

14/07/2026

Immutep Limited is pleased to announce the grant of a fourth U.S. patent covering eftilagimod alfa (efti) in combination with anti-PD-1/PD-L1 therapies for cancer treatment.

This latest patent further strengthens Immutep's intellectual property position and supports future development pathways for efti.

Marc Voigt, CEO of Immutep, said: “We are very pleased to add this fourth United States patent to our expanding patent portfolio covering eftilagimod alfa in combination with PD-1 pathway inhibitors. This represents a meaningful addition to our intellectual property estate. As we consider next steps for efti, this expanded IP estate supports future development pathways and business development opportunities.”

Read more: https://bit.ly/4w20loL

13/07/2026

Immutep Limited today announced a significant positive update from the investigator-initiated INSIGHT-003 Phase I trial, which is evaluating eftilagimod alfa (efti) in combination with MSD's KEYTRUDA® (pembrolizumab) and chemotherapy as a first-line treatment for advanced/metastatic non-small cell lung cancer (NSCLC) in 51 evaluable non-squamous patients.

The latest data showed a mature median overall survival (mOS) of 30.9 months, both in the overall study population and in patients with low or no PD-L1 expression (TPS

28/05/2026

Immutep Limited today announced positive results from a systematic evaluation of five clinical trials of eftilagimod alfa (“efti”) in combination with standard-of-care (SOC) therapies in late-stage cancer patients.

The analysis, involving 592 patients across four cancer indications, found treatment with efti plus SOC resulted in a significant increase in circulating absolute lymphocyte count (ALC), a blood-based measure of immune activity. More importantly, increased ALC was significantly associated with improved clinical outcomes in the E+SOC group, including a significant median overall survival improvement in ALC responders.

Immutep Chief Scientific Officer Frederic Triebel said: “These findings link the immune-activating effect of efti measured in patients’ blood with meaningful and significant survival improvements observed in previous clinical trials. Importantly, this highlights a key connection between efti’s mechanism of action and clinical efficacy.”

The data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

See the announcement here: https://bit.ly/49q0Kbp

19/05/2026

Immutep Limited CEO and Executive Director, Marc Voigt, spoke with ShareCafe to discuss the Company's next steps following the discontinuation of the TACTI-004 trial.

In the interview, Marc confirms the Company remains well funded with cash runway extending into the first half of 2028 and provides an update on the ongoing root cause analysis across clinical, analytical and manufacturing areas to determine the future pathway for eftilagimod alpha.

Marc also highlights the continued advancement of Immutep's broader pipeline, including the IMP761 autoimmune program, with first Phase I data expected to be presented at the EULAR conference in London on 4 June and upcoming milestones including an ASCO poster presentation in Chicago and completion of the root cause analysis, guided for Q3.

Watch the full interview here:

Immutep (ASX: IMM; NASDAQ: IMMP) is continuing development of its immunotherapy pipeline following the discontinuation of the Phase III TACTI-004 trial in non-small cell lung cancer. Chief Executive Officer Mark Voigt says the company remains well funded, with cash runway extending into the first ha...

15/04/2026

Immutep Limited is pleased to announce that the U.S FDA has granted Orphan Drug Designation (ODD) for efti for the treatment of Soft Tissue Sarcoma (STS), a rare cancer with significant unmet medical need.

This designation supports development in a rare cancer with significant unmet need and is backed by Phase II EFTISARC-NEO data showing encouraging tumour response and a favourable safety profile in combination with radiotherapy and KEYTRUDA.

CEO of Immutep, Marc Voigt said: “We are pleased that the FDA has recognised the potential of efti for patients with soft tissue sarcoma, a rare and difficult to treat cancer. As previously communicated, the Company is currently undertaking a comprehensive review and analysis following the discontinuation of its Phase III TACTI-004 trial and the outcome will influence the decision regarding any potential future clinical trial with efti. The FDA’s designation, based on very encouraging data from the EFTISARC-NEO trial, provides us with a potential direct step forward into a late-stage study in the neoadjuvant setting for STS.”

08/04/2026

Immutep has provided an investor update following the recent discontinuation of the TACTI‑004 Phase III trial in first‑line non‑small cell lung cancer.

A thorough root cause analysis is underway to understand factors contributing to the trial’s futility outcome. This work is essential not only for interpreting TACTI‑004, but also for guiding future development decisions across the broader efti pipeline.

Immutep's portfolio continues to include multiple differentiated assets, including IMP761 with upcoming data in early June.

Read the full update here:

19/03/2026

CEO & Executive Director, Marc Voigt, appeared on FNN to discuss the Phase III TACTI-004 trial update following the interim futility analysis, and the decision to discontinue the study.

In the interview Marc outlines the Company’s next steps, including a detailed review of the data and ongoing strategic planning, and highlights continued progress across Immutep’s broader clinical pipeline, with multiple programs advancing and further key milestones ahead.

Link to the full video here:

Immutep (ASX: IMM) (NASDAQ : IMMP) CEO & Executive Director Marc Voigt discusses the TACTI-004 trial update and outlines the company’s next steps, including ...

05/02/2026

Immutep Limited announces today that the TACTI-004 trial in first line non-small cell lung cancer has enrolled 378 patients, representing 50% of the trial's target enrolment.

Marc Voigt, CEO of Immutep, said, “The excellent pace of enrolment globally in the TACTI-004 trial speaks to the promise of efti and the need for more efficacious therapies in the first line setting for patients with advanced/metastatic non-small cell lung cancer."

The futility analysis and completion of patient enrolment remain on track for the first quarter and third quarter of CY2026, respectively.

Announcement here: https://bit.ly/4ahX2ju